Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiandan Tongluo tablets for acute ischemic stroke
ChiCTR2300067716Phase 4Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tiandan Tongluo tablets in ischemic stroke, sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Change in NIHSS score from baseline. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
Tiandan Tongluo tablets
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300067716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067716.